FDA approves Kalydeco (ivacaftor) as first and only CFTR modulator to treat eligible infants with CF as early as six months of age

30 April 2019 - Safety data from Phase 3 ARRIVAL study support treatment with Kalydeco in children ages six to <12 ...

Read more →

FDA approves first treatment for all genotypes of hepatitis C in paediatric patients

30 April 2019 - The U.S. FDA today approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of ...

Read more →

FDA approves first treatment for paediatric patients with lupus

26 April 2019 - The U.S. FDA today approved Benlysta (belimumab) intravenous infusion for treatment of children with systemic lupus erythematosus ...

Read more →

FDA implements new policies to advance the development of drugs to treat or prevent HIV, including in paediatric patients, as part of efforts to end HIV infection

19 March 2019 - The U.S. FDA today issued two final guidances for industry to help product sponsors understand the ...

Read more →

Allergan announces FDA approval of Avycaz (ceftazidime and avibactam) for paediatric patients

18 March 2019 - Label now includes new data on use of Avycaz for treatment of cUTI and cIAI in paediatric ...

Read more →

FDA approves Dupixent (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

11 March 2019 - Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation ...

Read more →

FDA accepts supplemental biologics license applications for Botox (onabotulinumtoxinA) for paediatric patients with upper and lower limb spasticity

7 March 2019 - Applications seek to extend use of Botox for patients 2 to 17 years old. ...

Read more →

FDA grants rare paediatric disease designation to odiparcil for the treatment of MPS VI

5 March 2019 - Inventiva eligible to receive priority review voucher upon approval of odiparcil for the treatment of MPS VI. ...

Read more →

Clementia granted rare paediatric disease designation by FDA for palovarotene for fibrodysplasia ossificans progressiva

11 February 2019 - Clementia Pharmaceuticals  today announced that the U.S. FDA has granted rare paediatric disease designation to palovarotene for ...

Read more →

RegenxBio receives rare paediatric disease designation for RGX-181 gene therapy for the treatment of CLN2 form of Batten disease

31 January 2019 - Novel, one-time investigational treatment for CLN2 disease designed to halt progression of this rare, paediatric, neurodegenerative disease. ...

Read more →

FDA approves use of 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) in children as young as 6 months of age

23 January 2019 - The 0.5 mL dose is now approved for use in children 6 months through 35 months of ...

Read more →

Bristol-Myers Squibb’s Sprycel (dasatinib) tablets now approved in combination with chemotherapy in certain paediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

2 January 2018 - Approval marks second paediatric leukaemia indication for Sprycel. ...

Read more →

Horizon Pharma announces FDA approval to expand the age range for Ravicti (glycerol phenylbutyrate) oral liquid to include newborns

27 December 2018 - Horizon Pharma today announced the U.S. FDA has approved a supplemental new drug application to expand the ...

Read more →

FDA approves Vaxelis, Sanofi and MSD’s paediatric hexavalent combination vaccine

26 December 2018 - The U.S. FDA has approved Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, ...

Read more →

FDA approves Nplate (romiplostim) for use in paediatric patients with immune thrombocytopenia

14 December 2018 - Application granted priority review designation. ...

Read more →